Treximet

Treximet is a brand name of naproxen/sumatriptan, approved by the FDA in the following formulation(s):

TREXIMET (naproxen sodium; sumatriptan succinate - tablet; oral)

• 
  Manufacturer: GLAXOSMITHKLINE
  
  Approval date: April 15, 2008
  
  Strength(s): 500MG;EQ 85MG BASE ^[RLD]

Has a generic version of Treximet been approved?

No. There is currently no therapeutically equivalent version of Treximet available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Treximet. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs
  Patent 6,060,499
  Issued: May 9, 2000
  Inventor(s): Plachetka; John R.
  Assignee(s): Pozen, Inc.
  This invention comprises a method of treating migraine in a human comprising co-timely administering of a therapeutically effective amount of a 5-HT agonist coordinated with a therapeutically effective amount of an analgesic, particularly a long-acting NSAID, and in some instances, doses below those ordinarily considered as minimum effective doses as to one or both 5-HT agonist and long-acting NSAID. Dosage forms are also included herein.
  
  Patent expiration dates:
  
  
  • August 14, 2017
    
    ✓ 
    Patent use: TREATMENT OF MIGRAINE
    ✓ 
    Drug product
  
  



• 
  Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
  Patent 6,586,458
  Issued: July 1, 2003
  Inventor(s): John R.; Plachetka
  Assignee(s): Pozen Inc.
  The invention is directed to methods and compositions that can be used in the treatment of headaches. In particular, methods and compositions are described involving the combination of a long-acting NSAID and a 5-HT agonist. Included among the long-acting NSAIDs are cyclo-oxygenase-2 inhibitors.
  
  Patent expiration dates:
  
  
  • August 14, 2017
    
    ✓ 
    Patent use: TREATMENT OF MIGRAINE
    ✓ 
    Drug product
  
  



• 
  Multilayer dosage forms containing NSAIDs and triptans
  Patent 7,332,183
  Issued: February 19, 2008
  Inventor(s): Plachetka; John R. & Kothapalli; Venkata Markandeya & Gilbert; Donna L.
  Assignee(s): Pozen Inc.
  The present invention is directed to multilayer pharmaceutical tablets in which an NSAID and a triptan are present in separate and distinct layers. The layers are in a side-by-side configuration, which allows the dissolution of triptan and NSAID to occur independently and immediately.
  
  Patent expiration dates:
  
  
  • October 2, 2025
    
    ✓ 
    Patent use: TREATMENT OF MIGRAINE
    ✓ 
    Drug product
  
  



• 
  Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
  Patent 8,022,095
  Issued: September 20, 2011
  Inventor(s): Plachetka; John R.
  Assignee(s): Pozen, Inc.
  The invention is directed to methods and compositions that can be used in the treatment of headaches. In particular, methods and compositions are described involving the combination of a long-acting NSAID and a 5-HT1B/1D agonist.
  
  Patent expiration dates:
  
  
  • August 14, 2017
    
    ✓ 
    Patent use: TREATMENT OF MIGRAINE
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • April 15, 2011 - NEW COMBINATION
  
  

See also...

• Treximet Consumer Information (Drugs.com)
• Treximet Consumer Information (Wolters Kluwer)
• Treximet Consumer Information (Cerner Multum)
• Treximet Advanced Consumer Information (Micromedex)
• Sumatriptan/Naproxen Consumer Information (Wolters Kluwer)
• Sumatriptan and naproxen Consumer Information (Cerner Multum)
• Sumatriptan and naproxen Advanced Consumer Information (Micromedex)